Researchers at the Doherty Institute, with collaborators from The University of Queensland’s National Biologics Facility and industry partner Biointelect Pty Ltd, are developing a novel therapeutic platform technology to combat viral pathogens with pandemic potential, thanks to the support of Health Security Systems Australia (HSSA), a division of DMTC limited.

Read the full article from the Doherty Institute here.